Skip to main content

Table 2 Linear regression of association between aortic stiffness and clinical factors with significant associations in italic

From: Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes

  AAD DAD PWV
Beta 95% CI P value Beta 95% CI P value Beta 95% CI P value
Age − 0.063 − 0.080;  0.046 0.0001  0.052  0.068; 0.036 < 0.0001 0.11 0.064; 0.16 < 0.0001
Male gender 0.13 − 0.47; 0.73 0.69 − 0.18 − 0.73; 0.36 0.50 0.11 − 1.39; 1.61 0.88
Body mass index 0.0042 − 0.051; 0.060 0.88 − 0.030 − 0.080; 0.020 0.24 − 0.30 − 0.17; 0.11 0.67
Duration of diabetes − 0.037 − 0.090; 0.016 0.17 − 0.040 − 0.090; 0.0050 0.08 0.087 − 0.044; 0.22 0.19
HbA1c  0.016  0.031;  0.00073 0.04 − 0.00037 − 0.014; 0.013 0.96 0.027 − 0.010; 0.065 0.15
Median HbA1c since diagnosis − 0.013 − 0.029; 0.0026 0.10 0.00084 − 0.013; 0.015 0.91 0.019 − 0.020; 0.058 0.33
Maximum HbA1c since diagnosis  0.011  0.020;  0.0014 0.02 − 0.0035 − 0.012; 0.0050 0.42 0.0083 − 0.016; 0.032 0.50
Microalbuminuria − 0.21 − 0.69; 0.26 0.37 − 0.21 − 0.64; 0.22 0.34 0.89 − 0.28; 2.06 0.13
24 h systolic BP  0.026  0.040;  0.011 0.001  0.020  0.034; − 0.0067 0.004 0.040 0.0014; 0.078 0.04
24 h diastolic BP − 0.0058 − 0.033; 0.021 0.67 − 0.0027 − 0.027; − 0.022 0.83 − 0.0015 − 0.068; 0.065 0.97
Total cholesterol 0.15 − 0.062; 0.36 0.16 0.056 − 0.14; 0.25 0.57 − 0.44 − 0.97; 0.081 0.10
Smoking 0.11 − 0.54; 0.76 0.74 0.098 − 0.49; 0.69 0.74 − 0.59 − 2.20; 1.02 0.47
Metformin 0.27 − 0.47; 1.01 0.47 0.35 − 0.31; 1.02 0.30 0.32 − 2.16; 1.51 0.73
Sulphonylurea − 0.57 − 1.06; − 0.08 0.02 0.34 − 0.79; 0.11 0.14 1.17 − 0.056; 2.39 0.06
Gliptin − 0.31 − 1.08; 0.46 0.43 0.14 − 0.57; 0.83 0.70 0.73 − 1.18; 2.64 0.45
Statin − 0.048 − 0.57; 0.47 0.86 − 0.13 − 0.60; 0.35 0.60 0.38 − 0.91; 1.67 0.56
Aspirin − 0.61 − 1.23; 0.012 0.06 − 0.51 − 1.08; − 0.51 0.07 1.10 − 0.46; 2.66 0.16
  1. Significant associations in italics
  2. Abbreviations as in Table 1